It’s a little penny stock that’s price almost doubled with this news. I’m skeptical.
You should be skeptical — that’s why double-blind random-assignment clinical trials are always necessary. I, OTOH, am skeptical and hopeful. Very hopeful, because antibody treatments are a proven technology in other applications.